Related Experiment Video
Updated: Mar 20, 2026
08:30
Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
Published on: May 10, 2022
2.7K
Increased Serum Soluble CD23 and Soluble IL-2R Levels in Haematologic Malignancies
Summary
Serum soluble CD23 and soluble IL-2 receptor levels are elevated in various hematological malignancies, serving as potential biomarkers. These markers show promise beyond lymphoproliferative disorders, excluding myelodysplastic syndrome.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Serum soluble CD23 (sCD23) and soluble IL-2 receptor (sIL-2R) are implicated in immune activation and hematological malignancies.
- These markers are utilized in monitoring lymphoproliferative disorders (LPD).
Purpose of the Study:
- To investigate serum sCD23 and sIL-2R levels in patients with hematological malignancies.
- To compare these levels with healthy controls and explore their utility as disease markers.
Main Methods:
- Serum samples from 21 hematological malignancy patients (10 LPD, 6 MM, 5 MDS) and 19 healthy controls were analyzed.
- Levels of sCD23 and sIL-2R were measured before treatment.
Main Results:
- Significantly elevated sIL-2R levels were observed in all patient groups compared to controls.
- Significantly higher sCD23 levels were found in the overall patient group, LPD, and MM patients.
- A positive correlation between sIL-2R and sCD23 was noted in LPD patients.
Conclusions:
- Elevated sCD23 and sIL-2R are potential biomarkers for LPD, multiple myeloma, and other hematological malignancies, but not MDS.
- Further research is needed to determine if these elevated levels result from immune system overactivity.
